iBloodPressure Reduces Hypertension in 71 Percent of Patients

iBloodPressure monitoring device and data platform for hypertension by Smart Meter, data showed that 71 percent of the patients with elevated levels of hypertension saw a reduction after only 3-½ months of using the iBloodPressure.

The iBloodPressure is a cellular-connected blood pressure monitoring system that automatically transmit blood pressure data to a remote patient monitoring system or electronic health record (EHR) system (including PointClickCare).

This provides more accurate tracking of blood pressure data and saves staff time in healthcare facilities by not having to manually write down or input results.

During the 14 weeks that results were noted, 88 percent of the participants who had the highest levels of blood pressure readings (Stage II) saw a reduction in blood pressure levels and 75 percent of them stepped down one stage or more.

Even the participants who started at a lower level of high blood pressure (Stage I), saw improvements, with 71 percent seeing a reduction in their results and 50 percent stepping down one stage or more.

“Using the cellular-connected iBloodPressure to track trends in a patient’s blood pressure is easy in any setting and provides greater access to the data for both the provider and the patient,” said Casey Pittock, Smart Meter CEO.

He added, “This ease-of-use improves patient engagement so that the patient will utilize the device as prescribed by their provider, which leads to better health outcomes.”

Smart Meter’s iBloodPressure is being utilized in many healthcare settings, including remote patient monitoring programs by physicians, long-term care facilities, and home care providers.

“We have seen great results with iBloodPressure from the many physician practices our Remote Patient Monitoring Platform and services support”, said Samson Magid, CEO of HealthSnap. “The health care professionals we serve appreciate the simplicity and reliability of this cellular blood pressure device from Smart Meter.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”